STXS Stereotaxis

Stereotaxis to Report Second Quarter 2020 Financial Results on August 6, 2020

Stereotaxis to Report Second Quarter 2020 Financial Results on August 6, 2020

ST. LOUIS, July 23, 2020 (GLOBE NEWSWIRE) -- (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 second quarter on Thursday, August 6, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.

What:Stereotaxis second quarter financial results conference call
  
When:Thursday, August 6, at 10:00 a.m. Eastern Time (7:00 a.m. PT)
  
Dial In Number:To access the live call, dial 888-394-8218 (US and Canada) or 786-789-4776 (International) and give the participant pass code 6170258.
  
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at
  
Call Replay:A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through August 13, 2020. To request access for a replay of the conference call, please .
  

About Stereotaxis

is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit .

Company Contacts:

David L. Fischel

Chairman and Chief Executive Officer

Kimberly Peery

Chief Financial Officer

314-678-6100

EN
23/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

Stereotaxis Announces FDA Clearance and Launch of Synchrony System ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab, offering an enhanced pr...

 PRESS RELEASE

Stereotaxis Reports 2025 Full Year Financial Results

Stereotaxis Reports 2025 Full Year Financial Results ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the year ahead,” said David Fischel, Chairman and CEO. “Th...

 PRESS RELEASE

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Resu...

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026 ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis fourth quarter and full ...

 PRESS RELEASE

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany. Klinikum Fürth is the first hospital in Germany to establish a leading heart rhythm program that incorporates the Genesis Robotic Magnetic Navigation System, advanced robotic technology that establishes a new standard of care for patients with arrhy...

 PRESS RELEASE

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can support patients with comple...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch